Regulatory and Compliance Updates news

• 

  30 April 2026

  MOL to acquire O&GD upstream assets in Hungary

  Buys 51% stakes in three Central Hungary concessions (~0.7 mboepd) plus Eastern Hungary assets (~0.2 mboepd), adding ~0.9 mboepd to group production; closing Q3 2026, subject to approvals.
• 

  30 April 2026

  Uniper receives preliminary approval for hydrogen-ready CCGT Unit 8 at Staudinger

  Regional authority grants preliminary approval for hydrogen-ready 890 MW CCGT; feasibility, emissions and habitat issues resolved; first partial permit due Q3 2026; project to enter capacity auctions
• 

  30 April 2026

  Petrobras posts 1Q26 own production record of 3.23 MMboed

  Ramp-up of multiple FPSOs and 10 new wells drove production gains (3.7% QoQ, 16.1% YoY); operated production 4.65 MMboed. Refining utilization, S10 diesel output and logistics records; LPG imports fell.
• 

  30 April 2026

  Lhyfe to supply green hydrogen to BMW Group’s Steyr R&D centre

  Multi-year deal to supply green hydrogen to an Austrian R&D site for development and validation of third-gen fuel-cell systems; first Austrian deliveries via bulk transport; RFNBO-certified.
• 

  30 April 2026

  Eli Lilly Q1 2026: Revenue up 56%, raises full‑year guidance

  EPS jumped ~170% reported (~156% non‑GAAP); volume growth offset lower realized prices; FDA approved oral GLP‑1 Foundayo; positive Phase‑3 readouts; four acquisitions announced
• 

  30 April 2026

  Merck & Co Q1 2026 Results — Sales Growth, Regulatory Approvals and Clinical Milestones

  Q1 revenue $16.3B; KEYTRUDA $8.0B. GAAP loss $1.72/sh, non-GAAP loss $1.28/sh after $9.0B Cidara charge. Announced Terns acquisition; raised 2026 sales to $65.8-67.0B and non-GAAP EPS $5.04-5.16

• 

  29 April 2026

  Biosimilars: stricter expectations for elastomeric closures

  Originator-level assessment required (functionality, E&L, CCI). Supplier data can't replace system-level testing. Risks: format migration, dual-market filings. Adopt platform approach; decide early.
• 

  29 April 2026

  SABIC Q1 2026 results

  Q1: adjusted EBITDA +25% to SAR4.15bn; revenue -6% to SAR26.15bn; adjusted net income SAR816m; realized $220m recurring EBITDA savings; divestments announced; urea capacity could rise 54%
• 

  29 April 2026

  Novo Nordisk: Denecimig (Mim8) reduces annualised bleeding rate in haemophilia A regardless of inhibitor status

  Denecimig (Mim8) cut annualised bleeding rates in haemophilia A (with/without inhibitors) in Phase 3 FRONTIER2 for once-monthly/weekly dosing; well tolerated, no thromboembolic events
• 

  29 April 2026

  GSK Q1 2026 — Specialty Medicines Drive Growth

  Q1 sales £7.6bn (+5% CER); Specialty Medicines £3.2bn (+14%). Core operating profit +10%, Core EPS +9%. Strong cash generation; 17p Q1 dividend. 2026 guidance and >£40bn 2031 target reaffirmed.
• 

  29 April 2026

  UPM approves Plywood demerger to create listed WISA Group

  Board approved plan to spin off a business into a new listed company; EGM approval pending; 1:1 share distribution; target completion Oct 31, 2026; listing expected early Nov 2026.
• 

  29 April 2026

  LANXESS and Fuelcare partner on European fuel biocide distribution

  EU-approved fuel biocides (Kathon FP 1.5, Preventol D2/FuelClear M15) to protect stored fuels—prevent microbial growth, sludge and corrosion; includes dosing tech and expanded service hubs.
• 

  29 April 2026

  UPM Q1 2026: Strong start led by decarbonization solutions

  Q1 sales €2,505m; comparable EBIT €274m (-5%); operating cash flow €89m; net debt €2,962m. Energy and biofuels strong. H1 comparable EBIT guidance €325–525m.
• 

  29 April 2026

  Neste Q1 2026 Interim Report

  Strong Q1: comparable EBITDA EUR 861m; cash flow before financing EUR 286m; renewable margin USD 856/t; oil refining margin USD 23.0/bbl; leverage 31.7%; volumes hit by maintenance
• 

  28 April 2026

  Plastic Ingenuity adopts PureCycle PureFive recycled PP for coffee lids

  Coffee lids now use 25-100% recycled polypropylene from a dissolution process; material retains virgin-like performance, has FDA food-contact clearance and GreenCircle certification.
• 

  28 April 2026

  GSK: FDA grants priority review and Breakthrough Therapy for bepirovirsen

  Phase III B-Well trials showed significantly higher functional cure rates and acceptable safety in chronic hepatitis B; drug is an antisense oligonucleotide; PDUFA date 26 Oct 2026
• 

  28 April 2026

  UPM joint venture with Sappi enters EU Phase II merger review

  EC opened Phase II on 28 Apr 2026. The proposed graphic-paper JV needs approvals in other jurisdictions; parties are cooperating and say the deal strengthens European supply resilience.
• 

  28 April 2026

  REMONDIS: Closing the Textile Loop

  Joint initiatives improve textile collection, sorting and recycling; mechanical and chemical recycling needed for mixed fibres. EPR funding and eco-modulation to fund infrastructure and boost reuse.
• 

  28 April 2026

  Borealis awarded EcoVadis Gold 2026

  EcoVadis score rose to 84/100 (from 80); improvements in environment, labour & human rights and ethics; sustainable procurement maintained; max score for policy implementation.
• 

  28 April 2026

  Boehringer Ingelheim’s survodutide achieves 16.6% weight loss in Phase III obesity trial

  Trial met co-primary endpoints; 85.1% achieved ≥5% weight loss vs 38.8% placebo; weight loss mainly fat with reduced waist circumference; GI events were mild–moderate; MASH trials ongoing
• 

  27 April 2026

  GSK efimosfermin granted FDA Breakthrough and EMA PRIME for MASH

  Phase II data: once-monthly long-acting FGF21 candidate improved fibrosis and disease resolution in F2/F3, well tolerated; phase III underway and F4 trials planned; condition drives liver transplants
• 

  27 April 2026

  Johnson & Johnson’s IMAAVY granted FDA Priority Review for wAIHA

  FDA granted Priority Review to nipocalimab sBLA for warm autoimmune hemolytic anemia after Phase 2/3 ENERGY showed durable hemoglobin responses and fatigue improvement; review ~6 months.
• 

  27 April 2026

  Johnson & Johnson: FDA approves CAPLYTA sNDA to reduce schizophrenia relapse risk

  FDA approved sNDA for CAPLYTA (lumateperone) to prevent relapse in schizophrenia. Phase 3 randomized‑withdrawal: 63% lower relapse risk (HR 0.37); 84% relapse‑free at 6 months; safety consistent.
• 

  27 April 2026

  Lilly to acquire Ajax Therapeutics for AJ1‑11095, a first‑in‑class Type II JAK2 inhibitor

  Lead program in Phase 1; POC data due late 2026. Designed to deliver deeper, more durable responses than current Type I JAK2 therapies. Deal may pay up to $2.3B, subject to closing.
• 

  27 April 2026

  Dow and RDM Group launch Multiboard CirculaRR — food-contact packaging from 100% recycled fibre and recycled PE

  Plastic-coated paper packaging made from recycled cartonboard and ISCC PLUS-certified recycled PE. Food-contact compliant, designed for mixed-paper recycling; suitable for frozen and dry pet food
• 

  24 April 2026

  BASF launches ELASTOSPRAY BMB biomass‑balance isocyanate for North American SPF market

  Drop-in biomass-balance isocyanate for SPF systems requires no reformulation, offers 21-29% lower product carbon footprints, REDcert2-verified, supports EPDs and local renewable-energy production
• 

  24 April 2026

  Mitsui Chemicals, Idemitsu Kosan and Sumitomo Chemical cleared by JFTC for Sumitomo’s PP and LLDPE integration into Prime Polymer

  MOU (Sept 2025) and definitive agreement (Dec 2025) formalize PP/LLDPE business integration; overseas antitrust reviews are ongoing and the deal will close after their clearance.
• 

  24 April 2026

  Chugai Q1 FY2026 Results

  Core rev ¥321.7B (+11.5%), core OP ¥163.3B (+17.1%), core net ¥118.6B (+19.6%). Launched Elevidys (DMD JP); Lunsumio+Polivy approved for LBCL. R&D: NXT007 switch, Enspryng (MOGAD), Foundayo US approval.
• 

  24 April 2026

  EMA recommends Redemplo for adults with familial chylomicronaemia syndrome (FCS)

  siRNA blocking APOC3 cut triglycerides 80% vs 17% in trial; lowered acute pancreatitis rates; given subcutaneously every 3 months; common AEs: hyperglycaemia, headache, nausea.
• 

  24 April 2026

  Kemira Q1 2026: Revenue and Profitability Down; Performance Actions Accelerated

  Q1 revenue and margins fell due to weak demand, pricing and FX; volumes stable. Operative EBITDA down; operating cash flow improved. Outlook unchanged; cost and pricing measures accelerated.